Overview

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The study is being done to study the impact of prophylactic administration of antiviral therapy as compared to initiation of antiviral therapy at the time of clinical recurrence of hepatitis C infection in liver transplant recipients.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Roche Pharma AG
Treatments:
Peginterferon alfa-2a
Ribavirin